接受疾病改善治疗的多发性硬化症患者的COVID-19疫苗接种:务实问题

IF 1.8 4区医学 Q2 Medicine Drugs of today Pub Date : 2022-12-01 DOI:10.1358/dot.2022.58.12.3455368

Ioan-Alexandru Chirap-Mitulschi, Constantin Ghimus, Andreea Raluca Chirap-Mitulschi, Sabina Antonela Antoniu, Raluca Dragomir

{"title":"接受疾病改善治疗的多发性硬化症患者的COVID-19疫苗接种:务实问题","authors":"Ioan-Alexandru Chirap-Mitulschi, Constantin Ghimus, Andreea Raluca Chirap-Mitulschi, Sabina Antonela Antoniu, Raluca Dragomir","doi":"10.1358/dot.2022.58.12.3455368","DOIUrl":null,"url":null,"abstract":"The SARS-COV-2 pandemic has been a global public health problem since 2019, with over 400 million reported cases, 6 million deaths, and significant economic and social damage. Overlapping SARS-CoV-2 infection in patients with chronic diseases, such as multiple sclerosis (MS), causes management problems, especially in patients treated with disease-modifying therapies. Studies investigating COVID-19 vaccination effectiveness have shown variability in postvaccination immune response that depends on the patient's background treatment, and special attention is required for anti-CD20 therapies. Existing data on the efficacy of COVID-19 vaccination in patients with MS undergoing disease-modifying treatment are summarized and critically evaluated in this article.","PeriodicalId":11397,"journal":{"name":"Drugs of today","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues.\",\"authors\":\"Ioan-Alexandru Chirap-Mitulschi, Constantin Ghimus, Andreea Raluca Chirap-Mitulschi, Sabina Antonela Antoniu, Raluca Dragomir\",\"doi\":\"10.1358/dot.2022.58.12.3455368\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The SARS-COV-2 pandemic has been a global public health problem since 2019, with over 400 million reported cases, 6 million deaths, and significant economic and social damage. Overlapping SARS-CoV-2 infection in patients with chronic diseases, such as multiple sclerosis (MS), causes management problems, especially in patients treated with disease-modifying therapies. Studies investigating COVID-19 vaccination effectiveness have shown variability in postvaccination immune response that depends on the patient's background treatment, and special attention is required for anti-CD20 therapies. Existing data on the efficacy of COVID-19 vaccination in patients with MS undergoing disease-modifying treatment are summarized and critically evaluated in this article.\",\"PeriodicalId\":11397,\"journal\":{\"name\":\"Drugs of today\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs of today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1358/dot.2022.58.12.3455368\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs of today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1358/dot.2022.58.12.3455368","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

自2019年以来，SARS-COV-2大流行一直是一个全球公共卫生问题，报告病例超过4亿例，死亡600万人，并造成重大经济和社会损失。多发性硬化症(MS)等慢性疾病患者的重叠SARS-CoV-2感染会导致管理问题，特别是在接受疾病缓解疗法治疗的患者中。调查COVID-19疫苗接种有效性的研究表明，疫苗接种后免疫反应的变异性取决于患者的背景治疗，需要特别注意抗cd20治疗。本文对MS患者接受疾病改善治疗的COVID-19疫苗接种效果的现有数据进行了总结和批判性评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues.

The SARS-COV-2 pandemic has been a global public health problem since 2019, with over 400 million reported cases, 6 million deaths, and significant economic and social damage. Overlapping SARS-CoV-2 infection in patients with chronic diseases, such as multiple sclerosis (MS), causes management problems, especially in patients treated with disease-modifying therapies. Studies investigating COVID-19 vaccination effectiveness have shown variability in postvaccination immune response that depends on the patient's background treatment, and special attention is required for anti-CD20 therapies. Existing data on the efficacy of COVID-19 vaccination in patients with MS undergoing disease-modifying treatment are summarized and critically evaluated in this article.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drugs of today 医学-药学

CiteScore

3.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： An international, peer-reviewed journal publishing monographs on new products entering the market and review articles. Since its inception in 1965, Drugs of Today has established a reputation for excellence in providing physicians and other key healthcare professionals with practical, up-to-date monographs on recently approved and launched drugs.

期刊最新文献

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma. Mitapivat for sickle cell disease and thalassemia. Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer. Anakinra as a potential treatment for COVID-19.